Ahmed M. El Kerdawy

Kasr El Aini Street
Cairo, C 11562, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Dual targeting of VEGFR-2 and FAK kinases by novel benzimidazole-oxadiazole hybrids: a potential approach in cancer therapy.

Dual targeting of VEGFR-2 and FAK kinases by novel benzimidazole-oxadiazole hybrids: a potential approach in cancer therapy.

Journal: RSC advances

Published: May 09, 2026

Discovery of novel chalcone-benzenesulfonamide conjugates as PPARγ agonists: Design, synthesis, and biological evaluation.

Discovery of novel chalcone-benzenesulfonamide conjugates as PPARγ agonists: Design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry

Published: February 09, 2026

Exploring pyrazolidinone and pyrazolidinedione scaffolds for Alzheimer's therapy: multitarget COX-2 inhibitors with anti-amyloid β, anti-tau, antioxidant, and neuroprotective activities.

Exploring pyrazolidinone and pyrazolidinedione scaffolds for Alzheimer's therapy: multitarget COX-2 inhibitors with anti-amyloid β, anti-tau, antioxidant, and neuroprotective activities.

Journal: RSC medicinal chemistry

Published: September 11, 2025

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study.

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, in vitro cytotoxicity, and molecular docking study.

Journal: RSC medicinal chemistry

Published: September 06, 2025

Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency.

Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency.

Journal: European journal of medicinal chemistry

Published: July 13, 2025

Quinolone as a Privileged Scaffold: A Brief Overview on Early Classical and Recent Advanced Synthetic Pathways, Innovative Neuroprotective Potential, and Structure-Activity Relationships.

Quinolone as a Privileged Scaffold: A Brief Overview on Early Classical and Recent Advanced Synthetic Pathways, Innovative Neuroprotective Potential, and Structure-Activity Relationships.

Journal: Drug development research

Published: April 26, 2025

Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents.

Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents.

Journal: European journal of medicinal chemistry

Published: April 25, 2025

Going beyond ATP binding site as a novel inhibitor design strategy for tau protein kinases in the treatment of Alzheimer's disease: A review.

Going beyond ATP binding site as a novel inhibitor design strategy for tau protein kinases in the treatment of Alzheimer's disease: A review.

Journal: International journal of biological macromolecules

Published: December 16, 2024

Discovery of 1-phenyl-1,2,3-triazole ureas as dual VEGFR-2/JNK-1 type II kinase inhibitors targeting pancreatic cancer.

Discovery of 1-phenyl-1,2,3-triazole ureas as dual VEGFR-2/JNK-1 type II kinase inhibitors targeting pancreatic cancer.

Journal: International journal of biological macromolecules

Published: December 02, 2024

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations.

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations.

Journal: BMC chemistry

Published: October 05, 2024

Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and In Vitro Cytotoxicity.

Furan- and Furopyrimidine-Based Derivatives: Synthesis, VEGFR-2 Inhibition, and In Vitro Cytotoxicity.

Journal: ACS medicinal chemistry letters

Published: September 06, 2024

Discovery of novel diaryl urea-oxindole hybrids as BRAF kinase inhibitors targeting BRAF and KRAS mutant cancers.

Discovery of novel diaryl urea-oxindole hybrids as BRAF kinase inhibitors targeting BRAF and KRAS mutant cancers.

Journal: Bioorganic chemistry

Published: August 05, 2024

Showing 1-12 of 63

Last Updated: 09/26/2026